Sector News

Reuters: Shire closer to deal to buy Baxalta

December 24, 2015
Life sciences

(Reuters) – Drug maker Shire Plc (SHP.L) has made a new acquisition offer for peer Baxalta International Inc (BXLT.N) that is roughly in line with the latter’s valuation expectations, making a deal in the coming weeks likely, people familiar with the matter said.

An agreement would successfully end Dublin-based Shire’s five-month pursuit of Bannockburn, Illinois-based Baxalta and create one of the world’s leading specialists in rare diseases.

Baxalta’s board rejected an all-stock offer from Shire in August, saying it had significantly undervalued the company.

While the exact terms of the deal could not be learned, Shire has now added enough cash to its previous all-stock offer for talks to advance, the people said. Baxalta would be valued in excess of $30 billion in any deal, one of the people added.

Baxalta shares were up 4.4 percent at $39.74 in afternoon trading in New York. American depository shares of Shire were trading down 0.4 percent at $194.40.

The sources asked not to be identified because the negotiations are confidential. Baxalta and Shire spokespeople offered no comment.

The challenging deal talks with Baxalta came after Shire pursued other deals in the rare diseases sector. Shire announced on Nov. 2 it was buying Dyax, which manufactures treatments for a rare genetic disease, for $5.9 billion.

A combination of Shire and Baxalta would add to the more than $600 billion in healthcare merger deals this year, which has been the busiest in the history of healthcare deal making.

Baxalta develops biotech treatments for rare blood conditions, cancers and immune system disorders. It was spun off was spun off from Baxter International Inc (BAX.N) in July.

By Carl O’Donnell and Pamela Barbaglia

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.